The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 3, 2001, Pages 179-186

  Chitolie, A ^a,b   Lawrie, A S ^a   Mackie, I J ^a   Harrison, P ^a   Machin, S J ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Activated protein C; Activated protein C resistance; Amidolytic assay; Factor V deficient plasma; Factor VIII; FV:Q506; Protein C activator

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; HEPARIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; HUMAN; LABORATORY TEST; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ACTIVATED PROTEIN C RESISTANCE; ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION TESTS; CHROMOGENIC COMPOUNDS; DEAMINO ARGININE VASOPRESSIN; ENDPOINT DETERMINATION; FACTOR V; FACTOR V DEFICIENCY; FACTOR VIII; FALSE NEGATIVE REACTIONS; GENOTYPE; HEPARIN; HUMANS; LUPUS COAGULATION INHIBITOR; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; PROTEIN S; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 0035014799     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200104000-00003     Document Type: Article

References (28)

1. Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
2. Venous thrombosis due to poor anticoagulant response to activated Protein C: Leiden thrombophilia study
3. Activated protein C resistance
4. 506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assay, pros and cons
5. Activated protein C resistance - A major risk factor for thrombosis
6. Mutation in blood coagulation factor V associated with resistance to activated protein C
7. 506Q mutation
8. Factor V Cambridge: A new mutation (Arg306→Thr) associated with resistance to activated protein C
9. A novel mutation of Arg306 of Factor V gene in Hong Kong Chinese
10. High prevalence of mutation in the FV gene within the UK population: Relationship to activated protein C resistance and familial thrombosis
11. World distribution of factor V Leiden mutation
12. Factor V Leiden is associated with repeated and reccurent unexplained fetal losses
13. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
14. Oral contraceptives and venous thromboembolism: Acquired APC resistance?
15. High risk of thrombosis in patients homozygous for factor V Leiden
16. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation
17. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls
18. Multicenter evaluation of a kit for activated Protein C resistance on various coagulation instruments using plasma from healthy individuals
19. A more discriminating test for APC resistance and possible screening test to include protein C and protein S
20. 506mutation of factor V (Factor V Leiden) and treated with oral anticoagulants
21. Specificity of 'clotting' methods for factor V Leiden
22. Diagnosis strategies in activated protein C resistance: Is genotyping still necessary?
23. Modified test for Activated Protein C resistance
24. The use of two different APC resistance assay systems provides optimal sensitivity and specificity for diagnosing genetic APC resistance
25. A chromogenic assay for activated protein C resistance
26. Simultaneous assay of free and total Protein S by ELISA using monoclonal and polyclonal antibodies
27. Role of factor VIII on activated protein C resistance ratio in inflammatory diseases
28. The influence of factor VIII on measurement of activated protein C resistance